

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting

FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)

10903 New Hampshire Avenue, Silver Spring, Maryland

September 19, 2017

MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Cindy Chee, PharmD

Division of Advisory Committee and Consultant Management

Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Harold J. Burstein, MD, PhD

Institute Physician

Dana-Farber Cancer Institute

Associate Professor of Medicine

Harvard Medical School

Boston, Massachusetts

Susan Halabi, PhD

Professor with Tenure

Department of Biostatistics and Bioinformatics

Duke University Medical Center

Durham, North Carolina

Philip C. Hoffman, MD

Professor of Medicine

The University of Chicago

Section of Hematology/Oncology

Department of Medicine

Chicago, Illinois

Grzegorz S. Nowakowski, MD

Associate Professor of Medicine and Oncology

Mayo Clinic Rochester

Rochester, Minnesota

Courtney J. Preusse, MA

(Consumer Representative)

Senior Research Administrator and CLIA

Operations Director

Clinical Research Division

Fred Hutchinson Cancer Research Center

Seattle, Washington

Alice T. Shaw, MD, PhD

Director

Center for Thoracic Cancers

Massachusetts General Hospital

Boston, Massachusetts

Thomas S. Uldrick, MD, MS

(Acting Chairperson)

Clinical Director

HIV & AIDS Malignancy Branch

Center for Cancer Research

National Cancer Institute

National Institutes of Health (NIH)

Bethesda, Maryland

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
September 19, 2017

MEETING ROSTER (cont.)

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Non-Voting)

Phuong Khanh (P.K.) Morrow, MD, FACP

(Industry Representative)
Global Product General Manager
Translational Sciences
Amgen
Thousand Oaks, California

TEMPORARY MEMBERS (Voting)

Ronald M. Bukowski, MD

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Bukowski Consulting, LLC
Highland Heights, Ohio

Richard D. Lumley, MS, EdD

(Patient Representative)
Kansas City, Missouri

Lance C. Pagliaro, MD

Professor of Oncology
Mayo Clinic College of Medicine and Science
Senior Associate Consultant
Division of Medical Oncology
Department of Oncology
Mayo Clinic
Rochester, Minnesota

Bruce Redman, DO

Professor of Medicine
Department of Internal Medicine
Division of Hematology/Oncology
University of Michigan Comprehensive Cancer
Center
Ann Arbor, Michigan

Ramaprasad Srinivasan, MD, PhD

Investigator and Head
Molecular Cancer Therapeutics Section
Urologic Oncology Branch
Center for Cancer Research
National Cancer Institute, NIH
Bethesda, Maryland

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director, Oncology Center of Excellence &
Acting Director
Office of Hematology and Oncology Products
(OHOP)
Office of New Drugs (OND), CDER, FDA

Julia Beaver, MD

Acting Director
Division of Oncology Products 1 (DOP1)
OHOP, OND, CDER, FDA

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
September 19, 2017

MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting) (cont.)

V. Ellen Maher, MD

Clinical Team Leader
DOP1, OHOP, OND, CDER, FDA

Sundeep Agrawal, MD

Clinical Reviewer
DOP1, OHOP, OND, CDER, FDA

Laura Fernandes, PhD

Statistician
Division of Biometrics V
Office of Biostatistics
Office of Translational Sciences, CDER, FDA

James Xu, MD

Clinical Reviewer
DOP1, OHOP, OND, CDER, FDA